Ibodutant

Drug Profile

Ibodutant

Alternative Names: MEN-15596

Latest Information Update: 10 Jun 2016

Price : $50

At a glance

  • Originator Menarini
  • Class Small molecules; Thiophenes
  • Mechanism of Action Neurokinin 2 receptor antagonists; Tachykinin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Irritable bowel syndrome

Most Recent Events

  • 31 May 2016 Menarini terminates its phase III trial for Irritable bowel syndrome in USA, Hungary, Latvia, Sweden, Slovakia, Germany and United Kingdom prior to May 2016(NCT02120027) (PO)
  • 18 May 2016 Menarini withdraws a phase III trial in Irritable bowel syndrome in South Korea, Singapore and Taiwan due to challenges in patient recruitment (NCT02320318)
  • 30 Jun 2015 Menarini completes a phase III trial in Irritable bowel syndrome in USA, Bulgaria, Czech Republic, France, Germany, Italy, Poland, Romania, Russia, Spain and United Kingdom (NCT02107196)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top